---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-004635"
form_type: "8-K"
ticker: "ANIK"
cik: "0000898437"
company_name: "Anika Therapeutics, Inc."
filed_at: "2026-07-14T21:00:16+00:00"
generated_at: "2026-07-14T21:02:07.200255+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Anika Therapeutics enters Fifth Amendment to credit agreement, $50M revolver due 2031

## Summary
- $50M senior revolving credit facility with Bank of America, maturity July 10, 2031.
- Option to increase commitments by up to $50M (total $100M) subject to lender approval.
- Interest rate: SOFR plus 0.25%-1.25% based on leverage ratio; commitment fee 0.20%-0.30% on unused portion.
- Financial covenants include max leverage and interest coverage ratios; first-priority lien on substantially all assets.
- Amendment reduces revolving facility from prior amount to $50M; certain lenders exit.

## SEC filing metadata
- accession: 0001171843-26-004635
- form_type: 8-K
- ticker: ANIK
- cik: 0000898437
- company_name: Anika Therapeutics, Inc.
- filed_at: 2026-07-14T21:00:16+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/898437/000117184326004635/0001171843-26-004635-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/898437/000117184326004635/f8k_071426.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-004635
- JSON: https://secwatch.observer/filing/0001171843-26-004635.json
- Plain text: https://secwatch.observer/filing/0001171843-26-004635.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.